UK Approves Breakthrough Breast Cancer Drug Enhertu for NHS Use Following Cost Settlement
London, Friday, 18 September 2026.
In September 2026, health authorities approved the life-extending drug Enhertu for NHS England, nearly doubling disease progression-free survival for around 1,000 patients following updated commercial and valuation framework agreements.
Regulatory Approval and Clinical Efficacy
On 17 September 2026, AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo officially secured approval from the UK’s National Institute for Health and Care Excellence (NICE) for Enhertu, targeting HER2-low metastatic breast cancer [1][2]. This regulatory breakthrough allows the National Health Service (NHS) to begin providing the treatment to approximately 1,000 eligible patients annually in England [3][4]. The decision reverses a previous 2024 rejection, marking a significant shift in the drug’s accessibility within the UK healthcare system [1][7].
Clinical Trial Performance Data
The approval follows data from the Phase 3 DESTINY-Breast04 trial, which demonstrated substantial survival benefits compared to standard chemotherapy [4][7]. Enhertu showed a median overall survival of 23.4 months versus 16.8 months for chemotherapy, representing a significant improvement in patient outcomes [4][7]. The treatment also nearly doubled progression-free survival to 9.9 months compared to 5.1 months for standard options, calculated as an increase of 94.118 percent in progression-free duration [1][7].
Regulatory Reversal and Cost Effectiveness
NICE had previously deemed Enhertu too costly for reimbursement in 2024, making it the only breast cancer treatment the agency failed to recommend between 2018 and 2024 [1][3]. The 2026 approval was facilitated by new commercial arrangements and updated cost-effectiveness thresholds implemented following a US-UK pharmaceutical trade deal finalized in Spring 2026 [1][2]. These changes included raising the Quality-Adjusted Life Year (QALY) threshold and adopting new quality-of-life assessment methods in August 2026 [2][3].
Implementation Timeline and Regional Access
While the treatment is available immediately in England and Northern Ireland, Wales is required to fund the treatment within 60 days of the final guidance’s publication, expected by mid-November 2026 [1][4]. The drug will initially be funded via the NHS Cancer Drugs Fund before moving to routine commissioning 90 days after the 15 September 2026 decision [3][7]. This aligns England with Scotland, where the drug has been available since 2023, and 26 other European countries [2][4].
Market Reaction and Future Outlook
Following the announcement, AstraZeneca stock closed at $162.89 on 16 September 2026, reflecting positive market sentiment regarding the oncology portfolio expansion [4]. Industry leaders note that delivering faster patient access requires continued collaboration across the healthcare system to value new medicines appropriately [3][4]. Advocates emphasize that while this decision is a victory, the prior delay underscores the need for systemic fixes to prevent future access gaps for metastatic patients [3][7].